Dr. Brody is Director of the Lymphoma Immunotherapy Program at Mount Sinai and a member of the Depart of Immunology. He has developed a robust clinical program and a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology to develop novel therapies for lymphomas and CLL with results published in top-tier journals including Nature Medicine and Cancer Discovery. Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity and regression of tumors throughout the body with clinical results published primarily for Follicular Lymphoma. Recently, his group discovered a novel approach ‘potentiating bystander killnig’ to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.
Dr. Brody’s research receives funding from numerous grantors e.g. the NIH, Cancer Research Institute, Damon Runyon Foundation, and the Lymphoma Research Foundation.